My Cart

ProS1

ProS1 Overview

English NameProstate-specific antigenApproved Drugs1
Drugs in Clinical Trials2Target SynonymP-30 antigen,Semenogelase,APS,Prostate-specific antigen,PSA,Kallikrein Related Peptidase 3,Gamma-Seminoprotein,Kallikrein-3,Seminin,Kallikrein 3, (Prostate Specific Antigen),EC 3.4.21.77,KLK2A1,HK3,KLK3,EC 3.4.21,EC:3.4.21.77
Highest Development StageApproved
English NameProstate-specific antigen
Target SynonymP-30 antigen,Semenogelase,APS,Prostate-specific antigen,PSA,Kallikrein Related Peptidase 3,Gamma-Seminoprotein,Kallikrein-3,Seminin,Kallikrein 3, (Prostate Specific Antigen),EC 3.4.21.77,KLK2A1,HK3,KLK3,EC 3.4.21,EC:3.4.21.77
Approved Drugs1
Drugs in Clinical Trials2
Highest Development StageApproved

ProS1 Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Human (1)

  • Tag

    His Tag (1)

  • Conjugate

    Unconjugated (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeatureOrder Now
PR1-H52H3
Human
HEK293
Human ProS1 Protein, His Tag
Add to Cart
Total: 1
  • 1

ProS1 Background

This gene is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. The encoded protein belongs to the subfamily B class of LIR receptors which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The receptor is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

ProS1 Synonyms

PROS, PS21, PS22, PS23, PS24, PS25, PSA, THPH5, THPH6

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Tb161-RAD402Tb161-RAD402Phase 2 ClinicalRadiopharm Theranostics LtdProstatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
GEA-408GEA-408Phase 2 ClinicalGenEros Biopharma Hangzhou LtdProstatic Neoplasms
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
AfalaApprovedMateria Medica Holding Research And Production CompanyRussian FederationProstatic Neoplasms; ProstatitisMateria Medica Holding Research And Production Company2014-01-01Prostatic Neoplasms; Prostatitis
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information